1991
DOI: 10.1016/0924-977x(91)90631-4
|View full text |Cite
|
Sign up to set email alerts
|

Zotepine: its clinical efficacy considered in relation to its effect on neurotransmitter-receptor systems

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

1993
1993
1993
1993

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 1 publication
0
2
0
Order By: Relevance
“…It is weIl known that HAL is a relatively strong ul-adrenergic antagonist. It should be added here that, according to some data, the u[-adrenergic activity of ZOT is greater than that of HAL and comparable to that oflevomepromazine (Puech and Martin, 1987;Ackenheil, 1991;Ackenheil et al, 1991).…”
Section: Discussionmentioning
confidence: 95%
See 1 more Smart Citation
“…It is weIl known that HAL is a relatively strong ul-adrenergic antagonist. It should be added here that, according to some data, the u[-adrenergic activity of ZOT is greater than that of HAL and comparable to that oflevomepromazine (Puech and Martin, 1987;Ackenheil, 1991;Ackenheil et al, 1991).…”
Section: Discussionmentioning
confidence: 95%
“…Zotepine (ZOT) is a relatively new atypical neuroleptic of the dibenzothiepine group. It blocks dopamine (DA) Dl and D2 receptors (Arima et al, 1986;Meltzer et al, 1989;Ackenhei/, 1991;Ackenheil et al, 1991). Clinically, ZOT appears to be a promising antipsychotic with a beneficial influence on both positive and negative schizophrenic symptoms, and a low extrapyramidal side effects (EPS)-inducing profile (Yamawaki, 1987;Fleischhacker et al, 1987;Barnas et al, 1991;Dieterle et al, 1991).…”
Section: Introducöonmentioning
confidence: 99%